Israeli - Kiebrania - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Israeli - Kiebrania - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Israeli - Kiebrania - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Israeli - Kiebrania - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Israeli - Kiebrania - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Israeli - Kiebrania - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Israeli - Kiebrania - Ministry of Health

trima israel pharmaceutical products maabarot ltd - diclofenac sodium - ג'ל - diclofenac sodium 1 % - diclofenac - diclofenac - for local treatment of rheumatic diseases, pain and non-infected inflammation.

Israeli - Kiebrania - Ministry of Health

trima israel pharmaceutical products maabarot ltd - diclofenac sodium - ג'ל - diclofenac sodium 1 %w/w - diclofenac - diclofenac - for local treatment of rheumatic diseases, pain and non-infected inflammation.

Israeli - Kiebrania - Ministry of Health

novartis israel ltd - budesonide - קפסולות - budesonide 400 mcg - budesonide - budesonide - maintenance treatment of bronchial asthma.

Israeli - Kiebrania - Ministry of Health

novartis israel ltd - ciprofloxacin as hydrochloride - תמיסה - ciprofloxacin as hydrochloride 3 mg/ml - ciprofloxacin - ciprofloxacin - corneal ulcers and conjunctivitis caused by susceptible gram positive and gram negative microorganisms for adults and pediatric patients above the age of 1 year. for localized or diffuse otitis externa accompanied by a strong inflammatory reaction and of which the strains are susceptible to ciprofloxacin, and for the acute flare-up of a chronic otitis media. in this case, a mucopurulent secretion comes through the perforated eardrum. pseudomonas aeruginosa is one of the organisms most likely to be found in this case. also in other infections of the ear in which pseudomonas aeruginosa and/or other susceptible strains may be demonstrated or suspected (for example with suppurating tympanic tubes), ciloxan can be used under the strict supervision of an ear specialist. it must be understood that this is not a routine treatment and that improper use must be avoided.